Literature DB >> 30406400

The Long Noncoding RNA HOST2 Promotes Gemcitabine Resistance in Human Pancreatic Cancer Cells.

Ning An1, Donghui Cheng2.   

Abstract

Our study was aimed to identify the fundamental role of lncRNA HOST2 in gemcitabine resistance regulation in human pancreatic cancer cells. The levels of HOST2 in pancreatic cancer cell lines were measured by quantitative real-time PCR (qRT-PCR). Due to high expression and strong gemcitabine resistance, Hs766T and AsPC-1 cell lines were selected to be knockdown the expression of HOST2 by transfection sh-HOST2. After manipulation of HOST2, the cell proliferation induced by gemcitabine was examined by CCK-8 assay. Next, colony formation ability of Hs766T and AsPC-1 cell lines was determined by clone-forming assay. At last, the relationship between HOST2 and cell apoptosis in Hs766T and AsPC-1 cell lines was evaluated by flow cytometry. QRT-PCR revealed that HOST2 was overexpressed in six pancreas neoplasm cell lines compared with normal cell lines HPDE6-C7. HOST2 expression levels in group resistant to gemcitabine were higher than the group sensitive to gemcitabine. Additionally, CCK-8 assay verified that cell proliferation was inhibited by sh-HOST2 with or without gemcitabine treatment. Furthermore, clone-forming assay revealed that colony formation ability was weakened by down-regulated HOST2 with or without gemcitabine treatment. Flow cytometry revealed that cell apoptosis induced by gemcitabine was promoted by sh-HOST2. In conclusion, down-regulated HOST2 inhibited proliferation and promoted apoptosis of pancreas cancer cells with or without gemcitabine treatment. Thus, HOST2 is a potential therapeutic target for gemcitabine chemoresistance in pancreatic neoplasms.

Entities:  

Keywords:  Gemcitabine; HOST2; LncRNA; Pancreatic neoplasms

Mesh:

Substances:

Year:  2018        PMID: 30406400     DOI: 10.1007/s12253-018-0486-5

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  26 in total

1.  Immunotherapy improves overall survival in pancreatic cancer.

Authors:  Susan Mayor
Journal:  Lancet Oncol       Date:  2015-01-16       Impact factor: 41.316

2.  Effects of long non-coding RNA HOST2 on cell migration and invasion by regulating MicroRNA let-7b in breast cancer.

Authors:  Peng-Wei Lu; Lin Li; Fang Wang; Yuan-Ting Gu
Journal:  J Cell Biochem       Date:  2018-03-07       Impact factor: 4.429

3.  A prospective randomised phase-II trial with gemcitabine versus gemcitabine plus sunitinib in advanced pancreatic cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.

Authors:  L Bergmann; L Maute; G Heil; J Rüssel; E Weidmann; D Köberle; S Fuxius; K Weigang-Köhler; W E Aulitzky; B Wörmann; G Hartung; B Moritz; L Edler; I Burkholder; M E Scheulen; H Richly
Journal:  Eur J Cancer       Date:  2014-11-05       Impact factor: 9.162

Review 4.  Pancreatic cancer: understanding and overcoming chemoresistance.

Authors:  Zhiwei Wang; Yiwei Li; Aamir Ahmad; Sanjeev Banerjee; Asfar S Azmi; Dejuan Kong; Fazlul H Sarkar
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-23       Impact factor: 46.802

5.  The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer.

Authors:  Zhihua Li; Xiaohui Zhao; Yu Zhou; Yimin Liu; Quanbo Zhou; Huilin Ye; YinXue Wang; Jinlong Zeng; Yadong Song; Wenchao Gao; ShangYou Zheng; Baoxiong Zhuang; Huimou Chen; Wenzhu Li; Haigang Li; Haifeng Li; Zhiqiang Fu; Rufu Chen
Journal:  J Transl Med       Date:  2015-03-12       Impact factor: 5.531

6.  Erratum to: Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer.

Authors:  Sören Müller; Susanne Raulefs; Philipp Bruns; Fabian Afonso-Grunz; Anne Plötner; Rolf Thermann; Carsten Jäger; Anna Melissa Schlitter; Bo Kong; Ivonne Regel; W Kurt Roth; Björn Rotter; Klaus Hoffmeier; Günter Kahl; Ina Koch; Fabian J Theis; Jörg Kleeff; Peter Winter; Christoph W Michalski
Journal:  Mol Cancer       Date:  2015-07-31       Impact factor: 27.401

7.  Gemcitabine treatment causes resistance and malignancy of pancreatic cancer stem-like cells via induction of lncRNA HOTAIR.

Authors:  Li Wang; Ping Dong; Weiguo Wang; Mingquan Huang; Bole Tian
Journal:  Exp Ther Med       Date:  2017-09-20       Impact factor: 2.447

8.  Effects of LncRNA-HOST2 on cell proliferation, migration, invasion and apoptosis of human hepatocellular carcinoma cell line SMMC-7721.

Authors:  Run-Tian Liu; Jing-Lin Cao; Chang-Qing Yan; Yang Wang; Cong-Jing An; Hai-Tao Lv
Journal:  Biosci Rep       Date:  2017-04-20       Impact factor: 3.840

Review 9.  Long non-coding RNA in pancreatic adenocarcinoma and pancreatic neuroendocrine tumors.

Authors:  Dimitrios Moschovis; Maria Gazouli; Maria Tzouvala; Antonios Vezakis; George Karamanolis
Journal:  Ann Gastroenterol       Date:  2017-08-04

10.  Effects of the Long Non-Coding RNA HOST2 On the Proliferation, Migration, Invasion and Apoptosis of Human Osteosarcoma Cells.

Authors:  Wei Wang; Xiao Li; Fan-Bin Meng; Zhen-Xing Wang; Ren-Tao Zhao; Chun-Yang Yang
Journal:  Cell Physiol Biochem       Date:  2017-08-31
View more
  8 in total

Review 1.  Role of taurine, its haloamines and its lncRNA TUG1 in both inflammation and cancer progression. On the road to therapeutics? (Review).

Authors:  Stella Baliou; Anthony M Kyriakopoulos; Demetrios A Spandidos; Vassilios Zoumpourlis
Journal:  Int J Oncol       Date:  2020-07-14       Impact factor: 5.650

Review 2.  Research updates on the clinical implication of long noncoding RNA in digestive system cancers and chemoresistance.

Authors:  Xinzhi Miao; Fang Wang; Tianyun Wang; Siti Razila Abdul Razak; Muhammad Amir Yunus; Ida Shazrina Ismail
Journal:  3 Biotech       Date:  2021-09-01       Impact factor: 2.893

3.  Long non‑coding RNA‑DUXAP8 regulates TOP2A in the growth and metastasis of osteosarcoma via microRNA‑635.

Authors:  Ting Yang; Jian Ping Guo; Fan Li; Chao Xiu; Hua Wang; Xian Liang Duan
Journal:  Mol Med Rep       Date:  2021-05-13       Impact factor: 2.952

Review 4.  Novel discoveries targeting gemcitabine-based chemoresistance and new therapies in pancreatic cancer: How far are we from the destination?

Authors:  Wenhao Luo; Gang Yang; Jiangdong Qiu; Jingyang Luan; Ying Zhang; Lei You; Mengyu Feng; Fangyu Zhao; Yueze Liu; Zhe Cao; Lianfang Zheng; Taiping Zhang; Yupei Zhao
Journal:  Cancer Med       Date:  2019-09-01       Impact factor: 4.452

5.  Epigenomics of Pancreatic Cancer: A Critical Role for Epigenome-Wide Studies.

Authors:  Rahul R Singh; Katie M Reindl; Rick J Jansen
Journal:  Epigenomes       Date:  2019-01-19

6.  Design of a novel antimicrobial peptide 1018M targeted ppGpp to inhibit MRSA biofilm formation.

Authors:  Zhou Jiale; Jiao Jian; Tan Xinyi; Xie Haoji; Huang Xueqin; Wang Xiao
Journal:  AMB Express       Date:  2021-03-26       Impact factor: 3.298

Review 7.  Long noncoding RNAs: role and contribution in pancreatic cancer.

Authors:  K T Ramya Devi; Dharshene Karthik; TharunSelvam Mahendran; M K Jaganathan; Sanjana Prakash Hemdev
Journal:  Transcription       Date:  2021-05-26

Review 8.  The multifaceted roles of long noncoding RNAs in pancreatic cancer: an update on what we know.

Authors:  Wenjia Zhou; Lu Chen; Chao Li; Rui Huang; Mian Guo; Shangwei Ning; Jingjing Ji; Xiaorong Guo; Ge Lou; Xinqi Jia; Junjie Zhao; Feng Luo; Chunlong Li; Zhaowei Qu; Shan Yu; Sheng Tai
Journal:  Cancer Cell Int       Date:  2020-02-05       Impact factor: 5.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.